Burning Rock Biotech Limited

BNR • Medical - Diagnostics & Research

Strong market move

BNR+11.22%

vs. previous close $10.78

$11.99

▲ +1.21 (+11.22%)

Current price

EarningsLatest report: Mar 31, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$12.61M

Growth

24.5%

Cash Flow

0/5

Trend

Negative

Evidence

Positive revenue growth · 79.0%Manageable debt level · 0.08Healthy liquidity · 2.99Weak profitability

Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: Mar 31, 2026, 12:00 AM UTCLast profile update: Sep 4, 2026, 12:16 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$11.99

Change11.22%

Shares Out1.05M

Market Cap$12.61M

52W Range6.79 - 41.72

Beta1.38

P/E-3.05

P/S0.31

P/B0.32

P/FCF-5.02

EV/Sales-0.53

EV/EBITDA8.95

Price$11.99

Change11.22%

Shares Out1.05M

Market Cap$12.61M

52W Range6.79 - 41.72

Beta1.38

P/E-3.05

P/S0.31

P/B0.32

P/FCF-5.02

EV/Sales-0.53

EV/EBITDA8.95

EV/FCF8.50

Earnings Yield-32.75%

FCF Yield-19.93%

Dividend Yield0.00%

Gross Margin74.67%

Oper. Margin-10.16%

Profit Margin-10.26%

Debt/Eq0.08

Current Ratio2.99

Quick Ratio2.76

Revenue 5Y24.55%

Volume133.63K

Avg Volume18.22K

EPS Surprise1.19

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

92/100

Why this score▼

Positive revenue growth · 79.0%Manageable debt level · 0.08Healthy liquidity · 2.99Weak profitability

Analyst view

Analyst sentiment and price target

BNR

Analyst sentiment

Based on 3 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Company Overview

IPO: 6/12/2020

Industry: Medical - Diagnostics & Research

P/B i: 0.32

Debt / Equity i: 0.08

Operating Margin: -10.16%

Net Margin: -10.26%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.08

Current Ratio: 2.99

Quick Ratio: 2.76

Status: Good

Insider Transactions

Recent executive and insider activity

Han Yusheng

Transaction: 06/26/2026

BUY

Change

+24,900

Price

$8.00

Filing

07/02/2026

Type

BUY

Han Yusheng

Transaction: 06/24/2026

BUY

Change

+250,000

Price

$8.00

Filing

07/02/2026

Type

BUY

Han Yusheng

Transaction: 06/23/2026

BUY

Change

+5,990

Price

$7.50

Filing

07/02/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Han Yusheng	BUY	+24,900	$8.00	06/26/2026	07/02/2026
Han Yusheng	BUY	+250,000	$8.00	06/24/2026	07/02/2026
Han Yusheng	BUY	+5,990	$7.50	06/23/2026	07/02/2026
Han Yusheng	BUY	+104,650	$7.45	06/22/2026	07/02/2026
Han Yusheng	BUY	+111,110	$9.00	06/16/2026	07/02/2026
Han Yusheng	BUY	+210,000	$9.25	06/12/2026	07/02/2026
Han Yusheng	BUY	+24,760	$8.74	06/11/2026	07/02/2026
Han Yusheng	BUY	+314,870	$17.36	03/31/2026	04/02/2026
DENG FENG	OTHER	0	Not reported	03/18/2026	03/18/2026
Xu Licen Lisa	OTHER	0	Not reported	03/17/2026	03/17/2026
Hu Xiaozhi	OTHER	+11,776	$3.33	03/17/2026	03/17/2026
Zhang Zhihong	OTHER	+56,000	$0.00	03/17/2026	03/17/2026
Zhang Zhihong	OTHER	0	Not reported	03/17/2026	03/17/2026
Han Yusheng	OTHER	+116,000	$0.00	03/17/2026	03/17/2026
Han Yusheng	OTHER	0	Not reported	03/17/2026	03/17/2026
Hayes Wendy W.	OTHER	0	Not reported	03/17/2026	03/17/2026

About the Company

Burning Rock Biotech Limited

Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.

Source - link

Peers

ADVB AEMD ALUR AMS AYTU CODX EKSO NVNO PMN PRPH

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Burning Rock Announces Founder's Purchase of Its ADSs

GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 73,141 of the Company's ADSs for US$618,217.72 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company's insider trading policy.

GlobeNewsWire

Why These High-Flying Stocks Came Back To Earth

Shares of Here Group, Zepp Health, Burning Rock Biotech and So-Young International all posted meteoric gains last year, but have given most of that back in 2026

Benzinga

Burning Rock Reports First Quarter 2026 Financial Results

GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026. Recent Business Updates Early Detection, Therapy Selection & MRD Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-03-12	-1.39699	-0.21	1.18699
2025-03-25	-1.39699	-1.08	0.31699
2024-12-03	-1.41035	-0.5	0.91035
2024-08-22	-1.48565	-0.14	1.34565
2024-05-29	-1.52284	-0.16	1.36284
2023-11-30	-1.80748	-2.3	-0.49252
2023-08-31	-1.88868	-1.8	0.08868
2023-05-30	-2	-2.6	-0.6
2023-03-28	-0.38	-3.1	-2.72
2022-11-15	-2.8	-3.1	-0.3
2022-08-31	-3.6	-3.7	-0.1
2022-05-31	-2.3	-3.9	-1.6